Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis

详细信息    查看全文

• 作者：Yinghui Liu ; Zuen Ren ; Jinghui Wang and Shucai Zhang
• 刊名：Thoracic Cancer
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：7
• 期：4
• 页码：406-414
• 全文大小：919K
• ISSN：1759-7714

文摘

The correlation between epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and EGFR sensitive mutation subtypes in advanced or metastatic non-small cell lung cancer (NSCLC) remains uncertain. We performed this meta-analysis to determine different clinical outcomes between patients with exon 19 deletion accepting EGFR-TKI therapy compared with those with exon 21 L858R mutation.